INNOVENT BIOLOGICS Aktie

 

The HSI concluded the midday up 358 points or 1.4% at 25,578. The HSCEI rose 108 points or 1.2% to 9,028. The HSTECH climbed 88 points or 1.65% to 5,484. The total half-day market turnover reached HKD130.588 billion.The Hang Seng Indexes Company announced the results of its quarterly review. INNOVENT BIO (01801.HK) was added to ......

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

The HSI opened 232 points higher, or 0.9%, at 25,452; the HSCEI opened 71 points higher, or 0.8%, at 8,991; and the HSTECH opened 61 points higher, or 1.1%, at 5,456.The Hang Seng Indexes Company announced the results of its quarterly review. INNOVENT BIO (01801.HK) was added to the HSI and HSCEI, opening 1.9% higher. CHINAHONGQ......

INNOVENT BIO (01801.HK) will be included in the HSI. The company's stock price opened 1.95% higher today (24th). With expanded gains, the stock peaked at HKD91.6, up nearly 5% at one point. It last printed at HKD90.3, up 3.5%, with a turnover of 2.2625 million shares, involving HKD204 million.The Hang Seng Indexes Company an......

SAN FRANCISCO and SUZHOU, China, Nov. 23, 2025 /PRNewswire/ -- Innovent Biologics (Stock Code: 01801.HK), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune,......

Innovent Biologics will join the Hang Seng Index next month in the latest quarterly review as the compiler of the city's stock benchmark presses ahead with its plan to increase the number of constituents to 100. The biotech firm, based in eastern Jiangsu province, has become the only new constituent of the blue-chip indicator, one month after it signed an US$11.4 billion outsourcing deal with Japan's Takeda Pharmaceuticals to co-develop and commercialise three specific investigational cancer......

Hang Seng Indexes Co. added biopharmaceutical company Innovent Biologics Inc. to its Hong Kong stock benchmark, the index compiler said following its quarterly review....

Hang Seng Indexes Company today announced the results of its review of the Hang Seng Family of Indexes for the quarter ended 30 September 2025. For the Hang Seng Index, INNOVENT BIO (01801.HK) will be added. The total number of constituents will increase from 88 to 89. All changes will be implemented after market close on 5 Dece......

Hang Seng Indexes Company announced the results of its review of the Hang Seng Family of Indexes for the quarter ended 30 September 2025. For the Hang Seng China Enterprises Index, CHINAHONGQIAO (01378.HK), INNOVENT BIO (01801.HK) and YUM CHINA (09987.HK) will be added, while ENN ENERGY (02688.HK), HAIDILAO (06862.HK) and NEW OR......

INDIANAPOLIS (dpa-AFX) - Innovent Biologics, Inc. (IVBXF, 1801.HK) announced that the Phase 3 clinical trial of mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) rece......

SAN FRANCISCO and SUZHOU, China, Nov. 19, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and......

SAN FRANCISCO and SUZHOU, China, Nov. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and......

INNOVENT BIO (01801.HK) announced a global strategic partnership with Japan's Takeda Pharmaceutical (4502.JP), covering several key oncology assets, including the next-generation IO cornerstone therapy IBI363, and reached licensing agreements for the in-progress projects IBI343 and IBI3001, CMBI released a research report sa......

Hong Kong-listed Innovent Biologics Inc. has formed a global partnership with Japan's Takeda Pharmaceutical Co. Ltd. to co-develop three cancer drugs, securing a $1.2 billion upfront payment in a deal valued at up to $11.4 billion. ... Read more...

INNOVENT BIO (01801.HK) recently announced a global collaboration agreement with Takeda Pharmaceutical (4502.JP), involving an upfront payment of US$1.2 billion and potential milestone payments of up to US$11.4 billion, according to JPMorgan's research report. This is the second-largest out-licensing agreement globally in te......

INNOVENT BIO (01801.HK) announced a strategic collaboration with Japan's Takeda Pharmaceutical, involving 3 research projects, naming IBI-363, IBI-343 and IBI-3001, BofA Securities published a research report saying. INNOVENT BIO will receive an upfront payment of US$1.2 billion, including a US$100 million equity investment ......

Takeda Pharmaceutical Co. has struck a deal with China's Innovent Biologics Inc. to co-develop cancer therapies, underscoring a surge of global pharma giants turning to Chinese biotech companies to create blockbuster drugs....

INNOVENT BIO (01801.HK) opened 9.9% higher this morning (22nd) at HKD95.5, with pre-market trading volume of 1.9026 million shares, involving HKD182 million.The group announced before the opening bell that, in order to accelerate the development of the next-generation IO and ADC cancer therapies to the global market, it entered ......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

BEIJING (dpa-AFX) - Takeda (TAK) has signed a license and collaboration agreement with Innovent Biologics to advance the development, manufacturing, and commercialization of two late-stage oncolog......